

Correction: A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells

In this article (Cancer Res 2013;73:5169–82), which was published in the August 15, 2013, issue of *Cancer Research* (1), the "Cytotoxic compounds" section on page 5170 was missing a reference and should read as follows:

The anti-tropomyosin compound TR100 was designed and synthesized by T.A. Hill and A. McCluskey (23). Cytochalasin D was purchased from Sigma-Aldrich. Compounds were solubilized in DMSO to give stock concentrations of 50 mmol/L (TR100) and 4 mmol/L (cytochalasin D).

The new reference #23 is as follows:

23. Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell LR, Chau N, et al. Inhibition of dynamin mediated endocytosis by the *Dynoles*—synthesis and functional activity of a family of indoles. *J Med Chem* 2009;52:3762–73.

The references in the article have been renumbered accordingly. The authors regret this error. The online version of the article has been corrected and no longer matches the print.

Reference

1. Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. *Cancer Res* 2013;73: 5169–82.

Published OnlineFirst August 29, 2013.

doi: 10.1158/0008-5472.CAN-13-2395

©2013 American Association for Cancer Research.